University of Bristol humanitarian medical IP commercialisation policy

The University of Bristol is committed to enabling and maximising benefits to society, government and industry, including in the developing world, that may arise from our research. The university’s policy when licensing its technology for commercial exploitation purposes is therefore to promote access to essential medicines in less developed countries where practical, whilst recognising the legitimate business concerns of our partners.

Bristol’s policy when licensing its technology for commercial exploitation purposes is:

1. to prosecute potential pharmaceutical active ingredient patent applications in less developed countries only as necessary (for example, to provide development and marketing leverage for new products, or to exert leverage over global licensees);

2. To include, where possible, provisions in its stand-alone commercial licences that seek to increase the availability of medicines at affordable prices in less developed countries

It expects its commercial licensing partners to appreciate and cooperate with this policy.

This Policy is a living document and may be subject to change by the University.

2 July 2012